Strategic Alliance: Innovent And SanegeneBio Target SiRNA Drug For Hypertension
Innovent Biologics and Sanegene Bio USA have entered a
collaboration to co-develop SGB-3908, an siRNA drug candidate targeting
angiotensinogen (AGT) for hypertension treatment. SGB-3908, an IND-enabling
stage siRNA drug, uses Sanegene Bio's LEAD (Ligand and Enhancer Assisted
Delivery) platform. Both companies will jointly develop SGB-3908, and Innovent
gains an exclusive option for future development, manufacturing, and
commercialization rights. After exercising its option, Innovent will pay
subsequent milestone payments and tiered royalties. The collaboration combines
Sanegene Bio's RNA technology strength with Innovent's clinical development
experience, aiming to accelerate SGB-3908's development for early benefits to
hypertension patients. Hypertension affects over 1 billion people globally, and
siRNA drugs like SGB-3908 present a potential long-term, compliance-friendly
solution compared to traditional anti-hypertension treatments.
More Information : https://www.techdogs.com/tech-news/pr-newswire/innovent-and-sanegenebio-enter-strategic-collaboration-to-develop-sirna-drug-for-the-treatment-of-hypertension
Comments
Post a Comment